Contact Us
Drug Search Results
More Filters [+]

Ridinilazole

Alternative Names: ridinilazole, smt19969, smt-19969, smt 19969
Latest Update: 2024-05-09
Latest Update Note: PubMed Publication

Product Description

Ridinilazole, previously known as SMT19969, is a novel antibacterial currently under development for the treatment of C. difficile. Its chemical name is 2,2?-bis(4-pyridyl)3H,3?H 5,5?-bibenzimidazole. The agent has a unique mechanism of action and is thought to interfere with cell division. It demonstrates rapid bactericidal activity against C. difficile.

Mechanisms of Action: Clostridium difficile Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Summit
Company Location: CAMBRIDGE MA 02142
Company CEO: Robert W. Duggan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ridinilazole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Communicable Diseases|Clostridium Infections

Phase 2: Clostridium Infections|Communicable Diseases|Diarrhea

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2017-001642-10

P3

Completed

Unknown

2021-11-19

Ri-CoDIFy 2

P3

Completed

Clostridium Infections|Communicable Diseases

2021-11-19

66%
2017-001641-27

P3

Completed

Unknown

2021-11-17

Ri-CoDIFy 1

P3

Completed

Communicable Diseases|Clostridium Infections

2021-11-17

Recent News Events

Date

Type

Title

05/09/2024

PubMed

 Fighting against Clostridioides difficile infection: Current medications.

02/02/2024

PubMed

 A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.

12/19/2023

PubMed

 Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.

02/14/2023

News Article

 Acurx is Setting a High Bar for New Treatments in C. diff

12/06/2022

News Article

 Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

10/20/2022

News Article

 Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

10/13/2022

News Article

 Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions